Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas

Journal of Clinical Pathology - Molecular Pathology

Volumn 50, Issue 5, 1997, Pages 247-253

  Holden, Joseph A ^a   Rahn, Mark P ^a   Jolles, Christopher J ^b   Vorobyev, Sergey V ^c   Bronstein, Igor B ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Special Gynecology and Oncology   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

DNA topoisomerase I; Immunohistochemistry; Ovarian carcinoma

Indexed keywords

DIAMINOBENZIDINE; DNA TOPOISOMERASE; FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; PEROXIDASE;

ARTICLE; CONTROLLED STUDY; EMBEDDING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE FIXATION;

EID: 0030661729     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.50.5.247     Document Type: Article

References (44)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65:635-92.
2. Gilmour DS, Pflugfelder G, Wang JC, Lis JT. Topoisomerase I interacts with transcribed regions in drosophila cells. Cell 1986;44:401-7.
3. Elgin SCR, Gilmour DS, Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin. Mol Cell Biol 1987;7:141-8.
4. Stewart AF, Schutz G. Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene. Cell 1987;50:1109-17.
5. Kretzschmar M, Meisterernst M, Roeder RG. Identification of human DNA topoisomerase I as a cofactor tor activator-dependent transcription by RNA polymerase II. Proc Natl Acad Sci USA 1993;90:11508-12.
6. Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature 1993;365:227-32.
7. Eng W, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharm 1989;34:755-60.
8. Bjornsti MA, Benedetti P, Viglianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumour drug camptothecin. Cancer Res 1989;49:6318-23.
9. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15:625-31.
10. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chao T, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14: 709-15.
11. Creemers GJ, Bolis G, Scarfone G, Lacave AJ, Guastalla JP, Despax R, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
12. Eng W, Pandit SD, Sternglanz R. Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I. J Biol Chem 1989;264:13373-6.
13. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 1995;55:1339-46.
14. Hsiang Y, Hertzberg R, Hecht S, Liu LF. Campthothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
15. Hsiang Y, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-5082.
16. Nitiss JL, Wang JC. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 1996;50:1095-102.
17. Madden KR, Champoux JJ. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res 1992;52:525-32.
18. Tamura H, Kohchi C, Yamada R, Ikeda T, Koiwai O, Petterson E, et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 1991;19: 69-75.
19. Tanizawa A, Bertrand R, Kohlhagen G, Tabuchi A, Jenkins J, Pommier Y. Cloning of chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation reponsible for camptothecin resistance. J Biol Chem 1993;268:25463-8.
20. Benedetti P, Fiorani P, Capuani L, Wang JC. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res 1993; 53:4343-8.
21. Rubin E, Pantazis P, Bharti A, Toppmeyer D, Biovanella B, Kufe D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem 1994;269:2433-9.
22. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumours: demonstration of tumour-type specificity and implications for cancer chemotherapy. Cancer Res 1994;54:539-46.
23. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AGJ, et al. Topoisomerase I and II activity in human breast, cervix, lung, and colon cancer. Int J Cancer 1994;59:607-11.
24. Bronstein IB, Vorobyev S, Timofeev A, Jolles CJ, Alder SL, Holden JA. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 1996;8:17-25.
25. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 1995;104: 45-59.
26. Martinchick JC, Rahn MP, Jolles CJ, Holden JA. DNA topoisomerase II-alpha: immunohistochemical staining for enzyme protein in tumours of ovarian origin. Int J Oncol 1997;10:1229-34.
27. Duguet M, Lavenot C, Harper F, Mirambeau G, De Recondo AM. DNA topoisomerases from rat liver: physiological variations. Nucleic Acids Res 1983;11:1059-74
28. Heck MMS, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988;85: 1086-90.
29. Baker SD, Wadkins RM, Stewart CF, Beck WT, Danks MK. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry 1995;19:134-45.
30. Florell SR, Martinchick JF, Holden JA. Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma. Anticancer Res 1996;16:3467-73.
31. Panayotis P, Kozielski AJ, Mendoza JT, Early JA, Hinz H, Giovanella BC. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumourigenic and tumourigenic cells in vitro. Int J Cancer 1993;53:863-71.
32. van der Zee AGJ, de Jong S, Keith WN, Hollema H, Boonstra H, de Vries EGE. Quantitative and qualitative aspects of topoisomerase I and II-alpha and -beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumours. Cancer Res 1994;54:749-55.
33. Bauman ME, Holden JA, Brown KA, Harker WG, Perkins SL. Differential immunohistochemical staining for DNA topoisomerase II-alpha and -beta in human tissues and for DNA topoisomerase II-beta in non-Hodgkin's lymphomas. Mod Pathol 1997;10:168-75.
34. Hwong C, Chen C, Shang H, Hwang J. Increased synthesis and degradation of DNA topoisomerase I during the initial phase of human T lymphocyte proliferation. J Biol Chem 1993;268:18982-6.
35. Mcleod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996;74:509-12.
36. 1 phase of the cell cycle and in DNA replication. J Cell Physiol 1992;151:478-86.
37. Lynch BJ, Guinee DG, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol. [In press.]
38. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987;50:917-25.
39. Holm C, Stearns T, Botstein D. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Biol 1989;9:159-68.
40. Charron M, Hancock R. DNA topoisomerase II is required for formation of mitotic chromosomes in chinese hamster ovary cells: studies using the inhibitor 4′-demethylepipodophyllotoxin 9-(4, 6-O-thenylidene-β-D-glucopyranoside). Biochemistry 1990;29:9531-7.
41. Castano IB, Heath-Pagliuso S, Sadoff BU, Fitzburgh DJ, Christman MF. A novel family of TRF (DNA topoisomerase I-related function) genes required for proper nuclear segregation. Nucleic Acids Res 1996;24:2404-10.
42. Muller MT, Pfund WP, Mehta VB, Trask DK. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J 1985;4:1237-43.
43. Buckwalter CA, Lin AH, Tanizawa A, Pommier YG, Cheng YC, Kaufmann SH. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res 1996;56:1674-81.
44. Danks MK, Garrett KE, Marion RC, Whipple DO. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res 1996; 56:1664-73.